River Road Asset Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 16.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 254,010 shares of the biopharmaceutical company's stock after selling 51,798 shares during the quarter. River Road Asset Management LLC's holdings in Pfizer were worth $6,739,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Raymond James Financial Inc. bought a new stake in Pfizer during the fourth quarter valued at about $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after buying an additional 6,977,587 shares in the last quarter. Fisher Asset Management LLC increased its position in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock worth $295,760,000 after buying an additional 4,938,209 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after buying an additional 4,726,549 shares during the period. Institutional investors own 68.36% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the stock. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective for the company. Guggenheim restated a "buy" rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Finally, Bank of America reissued a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.
Check Out Our Latest Research Report on Pfizer
Insider Activity at Pfizer
In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.
Pfizer Price Performance
Shares of Pfizer stock opened at $26.00 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a 50 day moving average of $26.29 and a 200 day moving average of $27.19. The firm has a market cap of $147.33 billion, a PE ratio of 18.44, a PEG ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company earned $0.10 EPS. The company's quarterly revenue was up 24.7% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.62%. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date was Friday, January 24th. Pfizer's dividend payout ratio is currently 121.99%.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
